Alcami Strengthens Leadership Team for Drug Product Manufacturing
Alcami Corporation, a prominent contract development and manufacturing organization (CDMO), has made significant strides by announcing key leadership appointments within its Drug Product division. These strategic moves aim to enhance operational excellence and commitment to delivering transformative medicines to patients worldwide under the direction of Tori E. Arens, President of Drug Product.
Introducing New Leaders
The appointment of Scott Jedrey as Vice President of Oral Solid Dose Operations signals an important shift in leadership. With an impressive 35-year journey at Alcami, Scott has amassed a wealth of experience in Manufacturing and Quality Operations. His leadership at the Manufacturing and Packaging facilities ensures that the company's reputation for quality is maintained and enhanced in the sphere of oral solid dose manufacturing.
Jeff Tripp has stepped into the role of Vice President of Sterile Operations, guiding the operations at the RTP facility. Jeff arrives with over four decades of experience in drug product and drug substance manufacturing. His background includes senior roles at prestigious companies, where he honed his expertise in sterile fill-finish processes, lyophilization, and efficient lean manufacturing systems. His contribution is expected to foster innovation and operational efficiency at Alcami's facilities.
Tyler Ewald has also been appointed as Vice President of Sterile Operations overseeing the Charleston facility. With over 15 years of diverse industry experience, Tyler's previous leadership roles in manufacturing and packaging operations, particularly in Wilmington, showcase his effective servant leadership style. His broad experience across multiple dosage forms prepares him to manage the challenges of manufacturing both small and large volume sterile products.
Looking Ahead: A Unified Vision for Success
Under Tori Arens’ leadership, the synergy created by the insights and expertise of the newly appointed Scott, Jeff, and Tyler ensures Alcami is well-equipped to scale its drug product manufacturing capabilities. This strategic alignment reflects Alcami's focus on delivering high-quality and life-changing therapies efficiently, showcasing agility and reliability.
About Alcami Corporation
Alcami Corporation has carved a niche for itself as a US-based contract development and manufacturing organization with a legacy of over 45 years dedicated to advancing pharmaceuticals and biologics. With comprehensive lab services, drug product manufacturing, cGMP pharmaceutical storage, and a robust suite of support services, Alcami stands as a vital partner in the industry. The organization operates under notable private equity ownership that includes GHO Capital, The Vistria Group, and Ampersand Capital Partners.
Frequently Asked Questions
What recent appointments were announced by Alcami Corporation?
Alcami announced key leadership roles for Scott Jedrey, Jeff Tripp, and Tyler Ewald within its Drug Product manufacturing operations.
Who is responsible for the Drug Product division at Alcami?
Tori E. Arens serves as the President of Drug Product at Alcami, guiding strategic directions.
What is the experience level of the new leadership team?
The new leaders bring a combined experience of over 90 years in the pharmaceutical and manufacturing sectors, ensuring strong industry expertise.
What areas will Scott Jedrey be focusing on in his new role?
Scott Jedrey will oversee Oral Solid Dose Operations, specifically leading the Manufacturing and Packaging facilities.
How does Alcami plan to enhance its manufacturing capabilities?
Through strategic appointments and leadership synergy, Alcami aims to improve the efficiency and innovation of its drug product manufacturing processes.
